Ruf P, Lindhofer H. Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood. 2001;98(8):2526–34.

Article  CAS  PubMed  Google Scholar 

Zeidler R, Mysliwietz J, Csanady M, et al. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer. 2000;83(2):261–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

European Medicines Agency. Catumaxomab (Korjuny®): summary of product characteristics. 2025. https://www.ema.europa.eu/en/medicines/human/EPAR/korjuny. Accessed 28 Mar 2025.

Ruf P, Gires O, Jäger M, et al. Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer. Br J Cancer. 2007;97(3):315–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ikegami T, Ishiki H, Kadono T, et al. Narrative review of malignant ascites: epidemiology, pathophysiology, assessment, and treatment. Ann Palliat Med. 2024;13(4):842–57.

Article  PubMed  Google Scholar 

Passebosc-Faure K, Li G, Lambert C, et al. Evaluation of a panel of molecular markers for the diagnosis of malignant serous effusions. Clin Cancer Res. 2005;11(19):6862–7.

Article  CAS  PubMed  Google Scholar 

Lindis Biotech and Pharmanovia. Lindis Biotech and Pharmanovia announce European marketing authorisation approval for a first-in-class treatment [media release]. 14 Feb 2025. https://pharmanovia.com.

European Medicines Agency. Catumaxomab (Korjuny®): European Public Assessment Report. 2004. https://www.ema.europa.eu/en/medicines/human/EPAR/korjuny. Accessed 28 Mar 2025.

Antoniewicz AA, Albert F, Wessels F, et al. Trifunctional anti-EpCAM/CD3 bsAb catumaxomab intravesically for high and intermediate risk non muscle invasive bladder cancer (HMR-NMIBC): interim analysis of a phase I study [abstract no. 2010P]. Ann Oncol. 2024;35(Suppl 2):S1160.

Article  Google Scholar 

Ruf P, Bauer HW, Schoberth A, et al. First time intravesically administered trifunctional antibody catumaxomab in patients with recurrent non-muscle invasive bladder cancer indicates high tolerability and local immunological activity. Cancer Immunol Immunother. 2021;70(9):2727–35.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Qi C, Wu S, Kim I-H, et al. Global multi-center phase I trial of the intraperitoneal infusion of anti-EpCAM x anti-CD3 bispecific antibody catumaxomab for advanced gastric carcinoma with peritoneal metastasis. J Clin Oncol. 2022;40(Suppl 16): e16102.

Article  Google Scholar 

Knödler M, Körfer J, Kunzmann V, et al. Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer. Br J Cancer. 2018;119(3):296–302.

Article  PubMed  PubMed Central  Google Scholar 

Sehouli J, Reinthaller A, Marth C, et al. Intra- and postoperative catumaxomab in patients with epithelial ovarian cancer: safety and two-year efficacy results from a multicentre, single-arm, phase II study. Br J Cancer. 2014;111(8):1519–25.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Baumann K, Pfisterer J, Wimberger P, et al. Intraperitoneal treatment with the trifunctional bispecific antibody catumaxomab in patients with platinum-resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group. Gynecol Oncol. 2011;123(1):27–32.

Article  CAS  PubMed  Google Scholar 

Fresenius Biotech GmbH. European Commission grants Orphan Drug Designation for the Removab® antibody to treat gastric cancer [media release]. 21 Nov 2006. http://www.fresenius.de.

Fresenius Biotech GmbH. Fresenius receives Orphan Drug Designation for antibody Removab® to treat patients with ovarian cancer [media release]. 19 Mar 2004. http://www.fresenius.de.

United States Food and Drug Administration. Orphan drug product designation database. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/. Accessed 26 Mar 2025.

Pharmanovia. Pharmanovia signs novel biologic in-licensing agreement with Lindis Biotech to commercialise catumaxomab for treatment of rare condition, malignant ascites [media release]. 19 Nov 2024. http://www.pharmanovia.com.

Lindis Biotech. Lindis Biotech announces publication of patient data highlighting the potential of trifunctional antibody catumaxomab for treatment of non-muscle-invasive bladder cancer in peer-reviewed journal [media release]. 1 Jun 2021. http://www.lindisbiotech.com.

Swedish Orphan Biovitrum. Swedish Orphan Biovitrum agrees with Fresenius Biotech to distribute Removab® [media release]. 21 Jan 2011. http://www.fresenius.com.

Fresenius Biotech GmbH. Fresenius sells biotechnology business [media release]. 28 Jun 2013. http://www.fresenius.de.

Frampton JE. Catumaxomab: in malignant ascites. Drugs. 2012;72(10):1399–410.

Article  CAS  PubMed  Google Scholar 

Jäger M, Schoberth A, Ruf P, et al. Immunomonitoring results of a phase II/III study of malignant ascites patients treated with the trifunctional antibody catumaxomab (anti-EpCAM × anti-CD3). Cancer Res. 2012;72(1):24–32.

Article  PubMed  Google Scholar 

Heiss MM, Murawa P, Koralewski P, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer. 2010;127(9):2209–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fossati M, Buzzonetti A, Monego G, et al. Immunological changes in the ascites of cancer patients after intraperitoneal administration of the bispecific antibody catumaxomab (anti-EpCAM×anti-CD3). Gynecol Oncol. 2015;138(2):343–51.

Article  CAS  PubMed  Google Scholar 

Ruf P, Kluge M, Jäger M, et al. Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients. Br J Clin Pharmacol. 2010;69(6):617–25.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Burges A, Wimberger P, Kümper C, et al. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study. Clin Cancer Res. 2007;13(13):3899–905.

Article  CAS  PubMed  Google Scholar 

Berek JS, Edwards RP, Parker LP, et al. Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: a phase II study. Int J Gynecol Cancer. 2014;24(9):1583–9.

Article  PubMed  Google Scholar 

Ott MG, Marmé F, Moldenhauer G, et al. Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II/III study in patients with malignant ascites. Int J Cancer. 2012;130(9):2195–203.

Article  CAS  PubMed  Google Scholar 

Heiss MM, Ströhlein MA, Bokemeyer C, et al. The role of relative lymphocyte count as a biomarker for the effect of catumaxomab on survival in malignant ascites patients: results from a phase II/III study. Clin Cancer Res. 2014;20(12):3348–57.

Article  CAS  PubMed  Google Scholar 

Wimberger P, Gilet H, Gonschior AK, et al. Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone. Ann Oncol. 2012;23(8):1979–85.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sehouli J, Pietzner K, Wimberger P, et al. Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS study. Med Oncol. 2014;31(8):76.

Article  PubMed  Google Scholar 

Pietzner K, Vergote I, Santoro A, et al. Re-challenge with catumaxomab in patients with malignant ascites: results from the SECIMAS study. Med Oncol. 2014;31(12):308.

Article  PubMed  Google Scholar